Comparison of Robotic-Assisted Versus Conventional Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.

Int J Med RobotSep 24, 2026
Clinical ResearchOrthopedic Surgery

Abdulazeez Omairi, Ryan Kenny, Oday Al-Dadah

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the clinical and radiological outcomes of robotic-assisted total knee arthroplasty (RTKA) compared to conventional total knee arthroplasty (CTKA) across 52 studies. RTKA showed superior accuracy in component alignment and reduced blood loss, although it had a longer operative time. Most patient-reported outcome measures (PROMs) exhibited minimal differences.

Key findings

  • RTKA demonstrated superior accuracy in component alignment compared to CTKA.
  • Operative time was longer for RTKA, while hospital length of stay was shorter.
  • RTKA resulted in lower blood loss compared to conventional techniques.
  • Most PROMs showed minimal differences between RTKA and CTKA.

Why it matters

Understanding the comparative effectiveness of RTKA versus CTKA is crucial for clinicians to make informed decisions regarding surgical options for knee arthroplasty, particularly in optimizing patient outcomes and recovery.

Source

PubMed · PMID 42775510

Published in Int J Med Robot. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.